<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38759575</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-3288</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><PubDate><Year>2024</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Heart &amp; lung : the journal of critical care</Title><ISOAbbreviation>Heart Lung</ISOAbbreviation></Journal><ArticleTitle>Outpatient management of Post-COVID syndrome - single center experience.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>143</EndPage><MedlinePgn>137-143</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.hrtlng.2024.05.004</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0147-9563(24)00090-6</ELocationID><Abstract><AbstractText Label="BACKGROUND">COVID patients continue to experience unremitting symptoms that extend far beyond the initial illness. While there is rapid accumulation of data on acute COVID treatment in hospitalized patients, little is known regarding post-COVID management.</AbstractText><AbstractText Label="OBJECTIVES">To describe our center's experience treating post-COVID sub-syndromes encountered in Post-COVID Lung Clinic.</AbstractText><AbstractText Label="METHODS">We retrospectively reviewed data on 98 post-COVID patients evaluated in our clinic between 07/01/2020-12/31/2022. We encountered three distinct post-COVID subtypes: 1) respiratory complaints associated with increased O2 requirements and abnormal CT findings (post-COVID interstitial lung disease [ILD]), 2) respiratory complaints associated with tachycardia (post-COVID dyspnea-tachycardia syndrome [DTS]). Post-COVID ILD patients (n = 28) received steroids in combination with cell cycle inhibitor (mycophenolate mofetil-MMF). Post-COVID DTS patients (n = 16) were treated with metoprolol. 3) A third, undifferentiated group presented with mild respiratory complaints and normal spirometry (n = 17) and was followed in clinic without initiation of a specific treatment.</AbstractText><AbstractText Label="RESULTS">In treated post-COVID ILD patients, mean oxygen requirements at rest (1.96 &#xb1; 1.79 L/NC) decreased to 0.89 &#xb1; 1.29 L/NC at 6 months follow-up, p = 0.005. In patients with post-COVID DTS, mean heart rate at rest decreased (98 &#xb1; 15 bpm to 79 &#xb1; 11 bpm) at 6 months follow-up, p = 0.023. 60 % of patients reported an improvement in exertional dyspnea.</AbstractText><AbstractText Label="CONCLUSIONS">Our descriptive study presents a single center outpatient COVID-19 clinic experience. We encountered 3 post-COVID sub-syndromes and describe their treatments: post-COVID interstitial lung disease [ILD] treated with a novel regimen of MMF and steroids, post COVID dyspnea-tachycardia syndrome [DTS] treated with metoprolol, and a third subgroup with mild undifferentiated symptoms without specific treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shedd</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States. Electronic address: christine.shedd@utsouthwestern.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaza</LastName><ForeName>Vaidehi</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bollineni</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banga</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohanka</LastName><ForeName>Manish R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ladikos</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wijesinha</LastName><ForeName>Marniker</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Luke D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joerns</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terada</LastName><ForeName>Lance</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timofte</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The University of Texas Southwestern Medical Center, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Heart Lung</MedlineTA><NlmUniqueID>0330057</NlmUniqueID><ISSNLinking>0147-9563</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>GEB06NHM23</RegistryNumber><NameOfSubstance UI="D008790">Metoprolol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013610" MajorTopicYN="N">Tachycardia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008790" MajorTopicYN="N">Metoprolol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ILD</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Tachycardia</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>17</Day><Hour>18</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38759575</ArticleId><ArticleId IdType="doi">10.1016/j.hrtlng.2024.05.004</ArticleId><ArticleId IdType="pii">S0147-9563(24)00090-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>